InVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar)

Catalog #SIM0028
Clone:
Denosumab
Reactivities:
Human

$217.00 - $7,526.00

$217.00 - $7,526.00

Choose an Option...
  • 100 mg - $7,526.00
  • 50 mg - $4,229.00
  • 25 mg - $2,942.00
  • 5 mg - $843.00
  • 1 mg - $217.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Denosumab making it ideal for research use. This Denosumab biosimilar reacts with human RANKL (receptor activator of nuclear factor kappa-B ligand) also known as CD254 and TRANCE (TNF-related activation-induced cytokine). RANKL is a 35 kDa type II membrane protein that belongs to the TNF superfamily. RANKL is expressed on activated T lymphocytes in the lung, thymus, and lymph nodes and on osteoclasts. RANKL has been implicated in the regulation of T cell and dendritic cell interactions as well as osteoclast differentiation. Additionally, RANKL was found to be critical for osteoclast differentiation. Denosumab is an inhibitor of RANKL which functions by decreasing the development of osteoclasts.

Specifications

Isotype Human IgG1, Īŗ
Recommended Isotype Control(s) RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen Human RANKL
Reported Applications Functional assays
Flow Cytometry
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <1EU/mg (<0.001EU/Ī¼g)
Determined by LAL gel clotting assay
Sterility 0.2 Āµm filtration
Production Purified from cell culture supernatant
Purification Protein A
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze.